A review of currently available data suggests that there is little or no difference in efficacy and safety between anti-VEGF biosimilars approved for neovascular age-related macular degeneration and their reference products.
However, more long-term results are needed and could potentially modify these conclusions, the study authors noted.
“The findings from our Cochrane review suggest that anti-VEGF biosimilars for neovascular AMD are comparable in safety and efficacy to their reference products. This is crucial as it supports the potential use of biosimilars as a viable, cost-effective